Compare Intanwijaya Internasional Tbk (INCI) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intanwijaya Internasional Tbk vs Organon Pharma Indonesia Tbk. — how do they compare? Intanwijaya Internasional Tbk trades at Rp800 (market cap 167.16B, 43.7K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Intanwijaya Internasional Tbk is the larger of the two by market cap. Which is the better fit depends on your goals.
| INCI | SCPI | |
|---|---|---|
Market Cap | 167.16B | 104.4B |
Volume | 43.7K | — |
Lot | 437 | — |
Turnover | 34.93M | — |
Average Price | 799.34 | — |
Value | 34.93M | — |
Indicative Equilibrium Price | 800 | — |
Indicative Equilibrium Volume | 2 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intanwijaya Internasional Tbk
PT Intanwijaya International Tbk (the Company) formerly named as PT Intan Wijaya Chemical Industry Tbk, was established in Jakarta based on the Notarial Deed No. 64 of Jony Frederik Berthold Tumbelaka Sinjal, S.H., dated November 14, 1981.The company's business field in in the Formaldehyde and Formaldehyde Resin Industries with the capacity of 96.000 metrics tons per annum in the form of liquid and 7.000 metric tons per annum in the form of powder and Hexamine 6.000 metric tons per annum.
Read more on INCI →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
